Bile Duct Cancer Market Research Report, By Type (Intrahepatic, Extrahepatic), Diagnosis (Blood Tests, Abdominal Imaging, Surgery), By Treatment (Chemotherapy, Radiotherapy), By End User (Hospital& Clinics, Academic Institutes) - Global Forecast till 2027
ID: MRFR/Pharma/3319-HCR | February 2021 | Region: Global | 90 pages
Market Scenario:
Bile duct cancer or cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, i.e., they show epithelial differentiation in the bile duct. It is a type of rare neoplasm. According to the National Cancer Institute, in 2014, there were an estimated 66,771 people living with liver and intrahepatic bile duct cancer in the United States. Moreover, the disease is expected to cause 28,920 deaths by the end of 2017 accounting for 4.8% of all cancer deaths. Rates for new liver and intrahepatic bile duct cancer cases have risen by an average 2.7% each year over the last 10 years. Death rates have been estimated to have risen by an average of 2.6% each year over 2005-2014. Such an increase in the prevalence of bile duct cancer has boosted the market. Additionally, rising healthcare expenditures, increasing awareness for the disease and investments in the R&D for treatment procedures is fuelling the market further. However, high cost of treatment and related side effects along with low healthcare expenditures in the developing economies is expected to restrain the market during the forecasted period.
The global bile duct cancer market is expected to grow at an approximate CAGR of 9.2% during the forecast period.
Intended Audience
- Pharmaceutical companies
- Biotechnological institutes
- Government and Private Laboratories
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
Figure 1: Global bile duct cancer market share, by Region
Sources: WHO, annual reports, press release, white paper, and company presentation
Segmentation
The global bile duct cancer market is segmented on the basis of types, diagnosis, treatment, and end users.
On the basis of types, the market is segmented into intrahepatic, extrahepatic, and others.
On the basis of diagnosis, the market is segmented into blood tests, abdominal imaging, surgery, and others. The diagnosis segment by abdominal imaging is sub segmented into endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), magnetic resonance cholangiopancreatography (MRCP), and others.
On the basis of treatment, the market is segmented into chemotherapy, radiotherapy, and others. The chemotherapy segment is sub segmented into 5-fluorouracil, gemcitabine, cisplatin, and others.
On the basis of end users, the market is segmented into hospital &clinics, academic institutes, research organizations and others.
Regional Analysis
The Americas dominates the global bile duct cancer market owing to a well-developed healthcare sector. Apart from this, increasing number of patients, increasing healthcare expenditure have boosted the growth of the market in the Americas. According to the Centers for Disease Control and Prevention, U.S. health care spending in 2015, reached $3.2 trillion or $9,990 per person which accounted for 17.8% of the total GDP.
Europe is the second largest bile duct cancer market, which is followed by Asia Pacific. Availability of funds for research, huge patient population and government support for research & development drives the European market.
Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies like India and China, and presence of huge opportunity in the market. According to Indian Brand Equity Fund, the per capita healthcare expenditure in India is estimated to grow at a CAGR of 5% during 2008-15 and reach USD 68.6 by 2015.
On the other hand, the Middle East & Africa has the least share in the global bile duct cancer market due to the presence of poor economy especially in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.
Research Methodology
Sources: WHO, annual reports, press release, white paper, and company presentation
Key players for global bile duct cancer market
The key players for the global bile duct cancer market are Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Europe), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd. (Middle East), Eli Lilly and Company. (U.S.), Sanofi (Europe), Fresenius Kabi AG (Europe), Mylan N.V. (U.S.), and others.
Frequently Asked Questions (FAQ) :
Global Bile Duct Cancer Market is expected to exhibit a strong 9.2% CAGR over the forecast period from 2016 to 2023.
The growing awareness about cancer treatments is the major driver for the Bile Duct Cancer Market.
High costs of treatment and unavailability in many emerging countries are the key restraints on Global Bile Duct Cancer Market.
The Americas are the dominant force in the Global Bile Duct Cancer Market.
Leading players in the global bile duct cancer market include Pfizer, Bristol-Myers Squibb, and Eli Lilly, among others.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Bile Duct Cancer Market, by Type
6.1 Introduction
6.2 Intrahepatic
6.2.1 Market Estimates & Forecast, 2020 – 2027
6.3 Extrahepatic
6.3.1 Market Estimates & Forecast, 2020 – 2027
6.4 Others
Chapter 7. Global Bile Duct Cancer Market, by Diagnosis
7.1 Introduction
7.2 Blood Tests
7.2.1 Market Estimates & Forecast, 2020 – 2027
7.3 Abdominal imaging
Market Estimates & Forecast, 2020 – 2027
7.3.1 Endoscopic retrograde cholangiopancreatography (ERCP)
7.3.2 Percutaneous transhepatic cholangiography (PTC)
7.3.3 Magnetic resonance cholangiopancreatography (MRCP)
7.3.4 Others
7.4 Surgery
7.4.1 Market Estimates & Forecast, 2020 – 2027
7.5 Others
7.5.1 Market Estimates & Forecast, 2020 – 2027
Chapter 8. Global Bile Duct Cancer Market, by Treatment
8.1 Introduction
8.2 Chemotherapy
Market Estimates & Forecast, 2020 – 2027
8.2.1 5-fluorouracil
8.2.2 Gemcitabine
8.2.3 Cisplatin
8.2.4 Others
8.3 Radiotherapy
8.3.1 Market Estimates & Forecast, 2020 – 2027
8.4 Others
8.4.1 Market Estimates & Forecast, 2020 – 2027
Chapter 9 Global Bile Duct Cancer Market, by End Users
9.1 Introduction
9.2 Hospitals & Clinics
9.2.1 Market Estimates & Forecast, 2020 – 2027
9.3 Academic Institutes
9.3.1 Market Estimates & Forecast, 2020 – 2027
9.4 Research Organizations
9.4.1 Market Estimates & Forecast, 2020 – 2027
9.5 Others
9.5.1 Market Estimates & Forecast, 2020 – 2027
Chapter 10. Global Bile Duct Cancer Market, by Region
10.1 Introduction
10.2 America
10.2.1 North America
10.2.1.1 US
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
Chapter 11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
Chapter 12 Company Profiles
12.1 Pfizer Inc.
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Bristol-Myers Squibb Company
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Teva Pharmaceutical Industries Ltd.
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Eli Lilly and Company.
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Sanofi
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 Fresenius Kabi AG
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Mylan N.V.
12.8.1 Overview
12.8.2 Product Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Others
Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of cancer industry
Chapter 14 Appendix
LIST OF TABLES
Table 1 Bile Duct Cancer Industry Synopsis, 2020 – 2027
Table 2 Global Bile Duct Cancer Market Estimates and Forecast, 2020 – 2027, (USD Million)
Table 3 Global Bile Duct Cancer Market by Region, 2020 – 2027, (USD Million)
Table 4 Global Bile Duct Cancer Market by Types, 2020 – 2027, (USD Million)
Table 5 Global Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)
Table 6 Global Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 7 Global Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 8 North America Bile Duct Cancer Market by Types, 2020 – 2027, (USD Million)
Table 9 North America Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)
Table 10 North America Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 11 North America Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 12 US Bile Duct Cancer Market by Type, 2020 – 2027, (USD Million)
Table 13 US Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)
Table 14 US Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 15 US Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 16 Canada Bile Duct Cancer Market by Type, 2020 – 2027, (USD Million)
Table 17 Canada Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)
Table 18 Canada Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 19 Canada Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 20 South America Bile Duct Cancer Market by Type, 2020 – 2027, (USD Million)
Table 21 South America Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)
Table 22 South America Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 23 South America Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 24 Europe Bile Duct Cancer Market by Type, 2020 – 2027, (USD Million)
Table 25 Europe Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)
Table 26 Europe Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 27 Europe Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 28 Western Europe Bile Duct Cancer Market by Types, 2020 – 2027, (USD Million)
Table 29 Western Europe Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)
Table 30 Western Europe Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 31 Western Europe Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 32 Eastern Europe Market by Type, 2020 – 2027, (USD Million)
Table 33 Eastern Europe Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)
Table 34 Eastern Europe Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 35 Eastern Europe Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 36 Asia Pacific Bile Duct Cancer Market by Types, 2020 – 2027, (USD Million)
Table 37 Asia Pacific Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)
Table 38 Asia Pacific Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 39 Asia Pacific Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)
Table 40 Middle East & Africa Bile Duct Cancer Market by Types, 2020 – 2027, (USD Million)
Table 41 Middle East & Africa Bile Duct Cancer Market by Diagnosis, 2020 – 2027, (USD Million)
Table 42 Middle East & Africa Bile Duct Cancer Market by Treatment, 2020 – 2027, (USD Million)
Table 43 Middle East & Africa Bile Duct Cancer Market by End Users, 2020 – 2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Bile Duct Cancer Market
Figure 3 Segmentation Market Dynamics for Global Bile Duct Cancer Market
Figure 4 Global Bile Duct Cancer Market Share, by Type 2020
Figure 5 Global Bile Duct Cancer Market Share, by Diagnosis 2020
Figure 6 Global Bile Duct Cancer Market Share, by Treatment 2020
Figure 7 Global Bile Duct Cancer Market Share, by End Users, 2020
Figure 8 Global Bile Duct Cancer Market Share, by Region, 2020
Figure 9 North America Bile Duct Cancer Market Share, by Country, 2020
Figure 10 Europe Bile Duct Cancer Market Share, by Country, 2020
Figure 11 Asia Pacific Bile Duct Cancer Market Share, by Country, 2020
Figure 12 Middle East & Africa Bile Duct Cancer Market Share, by Country, 2020
Figure 13 Global Bile Duct Cancer Market: Company Share Analysis, 2020 (%)
Figure 14 Pfizer Inc.: Key Financials
Figure 15 Pfizer Inc.: Segmental Revenue
Figure 16 Pfizer Inc.: Geographical Revenue
Figure 17 F. Hoffmann-La Roche Ltd: Key Financials
Figure 18 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 19 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 20 Bristol-Myers Squibb Company: Key Financials
Figure 21 Bristol-Myers Squibb Company: Segmental Revenue
Figure 22 Bristol-Myers Squibb Company: Geographical Revenue
Figure 23 Teva Pharmaceutical Industries Ltd.: Key Financials
Figure 24 Teva Pharmaceutical Industries Ltd.: Segmental Revenue
Figure 25 Teva Pharmaceutical Industries Ltd.: Geographical Revenue
Figure 26 Sanofi: Key Financials
Figure 27 Sanofi: Segmental Revenue
Figure 28 Sanofi: Geographical Revenue
Figure 29 Fresenius Kabi AG: Key Financials
Figure 30 Fresenius Kabi AG: Segmental Revenue
Figure 31 Fresenius Kabi AG: Geographical Revenue
Figure 32 Mylan N.V.: Key Financials
Figure 33 Mylan N.V.: Segmental Revenue
Figure 34 Mylan N.V.: Geographical Revenue
